Vollständiger Abstract
Worum geht es in dieser Arbeit?
Advanced therapy medicinal products are a rapidly expanding drug class based on genes, cells, and tissues, transforming the treatment of diseases, including haematologic cancers and genetic disorders, such as sickle cell disease and haemophilia. This review highlights that successful clinical implementation requires coordinated national strategies, regulatory support, sustainable funding, robust clinical and production infrastructure, and trained specialised personnel to ensure timely, safe, and equitable patient access.
Bibliografischer Nachweis
Publikationsdaten
- Autor:innen
- Rasmus Roost Aabling, Anne Louise Schacht Revenfeld, Maria Rusan
- Quelle
- Ugeskrift for Læger
- Publikation
- 2026-01-01
- Band / Ausgabe
- Nicht angegeben
- Seiten
- Nicht angegeben
- ISSN / ISBN
- 0041-5782, 1603-6824
- Zitationen
- 0 laut Crossref
- Referenzen
- 0 hinterlegt
Zitieren
Zitierfähiger Nachweis
Rasmus Roost Aabling, Anne Louise Schacht Revenfeld, Maria Rusan (2026). Advanced therapy medicinal products. Ugeskrift for Læger. https://doi.org/10.61409/v12251027